Forensic Analysis · Industrials / Manufacturing / Defense · as of Sep 25, 2026
Bruker Corp (BRKR)
A forensic read on Bruker Corp built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
D · Weak — demands caution
Forensic grade
Safe
Financial health
4.8
Distress distance
Clean
Earnings quality
4
Forensic signals
-87.8
P / E (ttm)
-0.4%
ROE
$9.1B
Market cap
0.30%
Dividend yield
2.1%
Revenue growth
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence, going concern, valuation). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
Bruker Corp earns a D (Weak — demands caution) forensic quality grade, and its balance-sheet distress test reads 4.8, placing it in the Safe zone. 4 forensic signals were flagged in its latest SEC filings, led by return on invested capital.
What the filings flag
0.9%
FY2025
Return on invested capital.Return on invested capital is 0.9% in the latest fiscal year and slipping across FY2023–FY2025 from 12.8%. After-tax operating profit was $342M in FY2023 and $44M in FY2025, with operating income at 14.7% of revenue in FY2023, 7.5% in FY2024 and 2.0% in FY2025. The capital base behind it grew +75% across FY2023–FY2025, from $2.7B to $4.7B, while the return fell 11.9 points, so the dollars added over that window earned less than the 12.8% the older base was already earning. FY2025's operating profit carried a $96M goodwill write-off, a $77M restructuring charge and a $31M asset write-down that alone took about 2.8 points off that year's return, so about 2.8 of the 11.9-point fall across FY2023–FY2025 is that charge landing in the latest year rather than the capital earning less. FY2024's operating profit carried a $28M asset write-down and a $25M restructuring charge that alone took about 0.8 points off that year's return; FY2024 sits between the two ends of FY2023–FY2025, so the charge shapes the path between them without moving the change across it.
+1.6%/yr
FY2023–FY2025
Share-count dilution.Diluted share count changed +3% over the last 2 years to FY2025 (+1.6%/yr). The count is growing: more stock was issued than repurchased over this window, so aggregate results grew faster than their per-share equivalents. That's ~1.6% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2023 has been diluted ~3%.
$96M
FY2025–FY2025
Goodwill impairments.Took $96M of goodwill writedowns across 1 year (FY2025 ($96M)). Writedowns mean past acquisitions underperformed what was paid for them.
-26%
FY2024→FY2025
Key fundamentals
Latest Revenue$3.44B
Revenue Growth YoY+2.1%
Revenue CAGR (2yr)+7.7%
Net Margin-0.3%
Free Cash Flow$43.3M
Return on Equity-0.4%
Debt / Equity0.76x
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Bruker Corp's actual 10-K/10-Q/8-K filings?